A detailed history of Burkehill Global Management, LP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Burkehill Global Management, LP holds 100,000 shares of BGNE stock, worth $22.7 Million. This represents 2.02% of its overall portfolio holdings.

Number of Shares
100,000
Holding current value
$22.7 Million
% of portfolio
2.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025

BUY
$175.1 - $226.71 $17.5 Million - $22.7 Million
100,000 New
100,000 $27.2 Billion

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Burkehill Global Management, LP Portfolio

Follow Burkehill Global Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Burkehill Global Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Burkehill Global Management, LP with notifications on news.